[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100561344":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":41,"responsibleParty":54,"collaborators":57,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":30,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":30,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":86,"whyStopped":30,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"McMaster University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Ketone monoester (KME) supplement","EXPERIMENTAL","Participants will be instructed to consume a ketone monoester (KME) supplement prior to each meal (3x\u002Fday) for 14 days.",[13],"Dietary Supplement: Ketone monoester (KME) supplement",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo supplement","PLACEBO_COMPARATOR","Participants will be instructed to consume a bottle of placebo supplement prior to each meal (3x\u002Fday) for 14 days.",[19],"Dietary Supplement: Placebo supplement",[21,27],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DIETARY_SUPPLEMENT","15g of a KME supplement orally consumed 3x daily for 14 days. This dosing protocol raises plasma β-OHB consistently during the waking hours. Oral KME will be provided in opaque bottles labelled A or B to maintain condition blinding. Each bottle will contain a drink providing 15g of a KME supplement: \\[R\\]-3-hydroxybutyl \\[R\\]-3-hydroxybutyrate (ΔG®, TDeltaS, Oxford, UK).",[9],[26],"[R]-3-hydroxybutyl [R]-3-hydroxybutyrate (ΔG®, TDeltaS, Oxford, UK)",{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":30},"50mL taste-match inert calorie-free placebo drink orally consumed 3x daily for 14 days. Oral placebo will be provided in opaque bottles labelled A or B to maintain condition blinding.",[15],null,[32],{"name":33,"affiliation":5,"role":34},"Jeremy Walsh, PhD","PRINCIPAL_INVESTIGATOR",[36],{"name":37,"role":38,"phone":39,"phoneExt":30,"email":40},"Walsh","CONTACT","(905) 525-9140","walshj18@mcmaster.ca",[42],{"facility":5,"status":30,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":30},"Hamilton","Ontario","L8S 4K1","Canada","CA",{"type":49,"coordinates":50},"Point",[51,52],-79.84963,43.25011,{"lat":52,"lon":51},{"type":34,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"Jeremy Walsh","Assistant Professor",[58],{"name":59,"class":6},"Heart and Stroke Foundation of Canada","100561344","phase-2--ohb-supplementation-and-brain-health-in-older-adults-100561344",false,"NCT06588946","Β-OHB Supplementation and Brain Health in Older Adults","The Effect of Exogenous Β-OHB Supplementation on Cerebral Blood Flow and Functional Brain Characteristics in Adults with Subjective Cognitive Decline","Inclusion Criteria:\n\n* Being objectively cognitively normal as determined by a Montreal Cognitive Assessment (MoCA) score ≥26 with independent living and ambulating\n* SCD will be determined using the Prospective-Retrospective Memory Questionnaire (PRMQ) following the SCD Initiative Working Group framework\n\nExclusion Criteria:\n\n* A diagnosis of mild cognitive impairment, dementia, or psychiatric and\u002For mood disorders (e.g., major depression)\n* MoCA score \\\u003C26\n* Diagnosis of cardiometabolic disease (e.g., hypertension, type 2 diabetes)\n* Obesity (BMI \\>30 kg\u002Fm2)\n* History of heart attack or stroke\n* History of smoking\n* Currently following a ketogenic diet or taking ketogenic supplements\n* Having MRI contraindications\n* Participants with literacy, visual, hearing, and\u002For speech issues, as well as individuals who are not proficient in English will not be eligible for this trial","ALL","55 Years","75 Years",{"count":71,"type":72},48,"ESTIMATED","INTERVENTIONAL",[75],"PHASE2","The goal of this randomized placebo controlled crossover trial is investigate the effects of short-term ketone monoester (KME) supplementation to brain function in older adults with subjective cognitive decline. We will test the hypothesis that KME supplementation will increase cerebral blood flow and improve resting-state functional connectivity in the brain compared to placebo supplementation in older adults with subjective cognitive decline.\n\nParticipants will be randomly assigned to either placebo of KME supplementation for 14 days. Following a washout period, participants will complete the alternate condition for 14 days. Outcome measures will be assessed before and after each intervention period.",[78],"Subjective Cognitive Decline",[80,81,82,83,84,85],"early-stage dementia","ketone monoester supplementation","cerebral blood flow","cognition","resting state functional magnetic resonance imaging","placebo","NOT_YET_RECRUITING","2025-02-24",{"date":89,"type":90},"2025-02-26","ACTUAL",{"date":92,"type":72},"2025-03",{"date":94,"type":72},"2027-08",{"name":5,"class":6},1]